Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of VGL101 in Adult-Onset Leukoencephalopathy With Axonal Spheroids and Pigmented Glia (ALSP)
2022-502505-15-00Phase 3Completed
- Sponsor
- Vigil Neuroscience
- Start
- Jul 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 5
01
Overview
Phase 3 trial of iluzanebart in CSF1R-related leukoencephalopathy (ALSP), sponsored by Vigil Neuroscience. Started Jul 2023; status: completed.
02
Drugs
iluzanebart
03
Conditions
CSF1R-related leukoencephalopathy (ALSP)
Beyond the preview
Go deeper on 2022-502505-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502505-15-00.